CBGGF.OTC.PinkChain Bridge I
10-Q: Chain Bridge I Reports Q3 2024 Results, Faces Liquidation Concerns Despite Business Combination Agreement
Sentiment:
Quarterly Report
Chain Bridge I's Q3 2024 report reveals a net income of $624,000, but also highlights substantial doubt about the company's ability to continue as a going concern due to its upcoming mandatory liquidation date.
Delay expectedThe company postponed its extraordinary general meeting of shareholders from November 8, 2024 to November 14, 2024 to allow additional time for the company to engage with its shareholders.
Capital raiseThe company entered into non-redemption agreements with investors who agreed to rescind or reverse previous elections to redeem shares.The company may issue additional shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination.
Worse than expectedThe company's financial statements raise substantial doubt about its ability to continue as a going concern due to the mandatory liquidation date.The company has a working capital deficit and a limited cash balance, which could hinder its ability to operate effectively.The company's net loss for the nine-month period is a negative indicator of its financial health.
Summary
- Chain Bridge I, a blank check company, reported a net income of $624,000 for the three months ended September 30, 2024, a significant turnaround from the $472,000 net loss in the same period of 2023.
- The company's Q3 2024 income was primarily driven by a gain in the fair value of derivative liabilities of $882,000 and investment income from the trust account of $148,000.
- For the nine months ended September 30, 2024, the company reported a net loss of $1.1 million, compared to a net income of $4.1 million for the same period in 2023.
- The company's cash balance stood at $428,625 as of September 30, 2024, with a working capital deficit of $486,351.
- Chain Bridge I has until November 15, 2025, to complete a business combination, after which it must liquidate, raising substantial doubt about its ability to continue as a going concern.
- The company has entered into a business combination agreement with Phytanix Bio, expected to close in the fourth quarter of 2024, which will result in a new holding company called Phytanix, Inc.
- The company's Class A ordinary shares are subject to possible redemption, with 1,006,683 shares classified as temporary equity at a redemption value of $11,410,382 as of September 30, 2024.
- The company has outstanding warrants, including 11,500,000 public warrants and 10,550,000 private placement warrants, which are exercisable for Class A ordinary shares under certain conditions.
Sentiment
Score: 3
Explanation: The document presents a mixed picture with a positive Q3 net income but significant concerns about the company's ability to continue as a going concern and the risk of liquidation. The delisting from Nasdaq and the need for non-redemption agreements further contribute to a negative sentiment.
Positives
- The company achieved a net income of $624,000 in Q3 2024, a significant improvement compared to the net loss in the same period last year.
- The company has a business combination agreement in place with Phytanix Bio, which is expected to close in the fourth quarter of 2024.
- The company's investment income from the trust account contributed positively to the financial results.
Negatives
- The company has a working capital deficit of $486,351 as of September 30, 2024.
- The company faces a mandatory liquidation date of November 15, 2025, raising substantial doubt about its ability to continue as a going concern.
- The company reported a net loss of $1.1 million for the nine months ended September 30, 2024.
- The company's Class A ordinary shares are subject to possible redemption, which could impact the company's capital structure.
Risks
- The company's ability to continue as a going concern is in doubt due to the mandatory liquidation date of November 15, 2025.
- Failure to complete the business combination with Phytanix Bio by the deadline will result in liquidation.
- The company's working capital deficit could hinder its ability to operate effectively.
- The company's warrants may expire worthless if a business combination is not completed.
- The company's Class A ordinary shares are subject to possible redemption, which could impact the company's capital structure.
Future Outlook
The company is focused on completing its business combination with Phytanix Bio by November 15, 2025. If the business combination is not completed by this date, the company will be forced to liquidate.
Management Comments
- Management has determined that the liquidity condition and the date for mandatory liquidation and subsequent dissolution raises substantial doubt about the Company's ability to continue as a going concern.
- Management concluded that our internal control over financial reporting was effective as of September 30, 2024.
Industry Context
The document reflects the challenges faced by many SPACs in finding suitable merger targets and the pressure to complete a business combination within a specified timeframe. The delisting from Nasdaq and the subsequent move to the OTC market is a common occurrence for SPACs that fail to meet listing requirements.
Comparison to Industry Standards
- The financial performance of Chain Bridge I is mixed, with a positive net income in Q3 2024 but an overall net loss for the nine-month period, which is not uncommon for SPACs in their pre-merger phase.
- The company's cash position and working capital deficit are typical for SPACs that have not yet completed a business combination, as they primarily rely on funds held in trust and external financing.
- The risk of liquidation due to the mandatory deadline is a common concern for SPACs, and Chain Bridge I's situation is not unique in this regard.
- The business combination agreement with Phytanix Bio is a positive step, but the success of the merger and the future performance of the combined entity will be critical for the company's long-term viability.
- The delisting from Nasdaq and the move to the OTC market is a negative development, but it is not uncommon for SPACs that fail to meet listing requirements. This is similar to other SPACs that have faced delisting due to not completing a business combination within the required timeframe, such as those that have been delisted from the NYSE and Nasdaq.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer | Roger Lazarus | Andrew Kucharchuk | 2024-04-01 | Resignation of previous CFO |
Related Party Transactions
- The company has entered into various agreements with related parties, including loans, administrative services agreements, and share transfers.
- CBG and CB Co-Investment have provided loans and services to the company.
- Fulton AC has provided loans and services to the company.
Stakeholder Impact
- Shareholders face the risk of liquidation if the business combination is not completed by the deadline.
- Shareholders who redeemed their shares received a pro rata portion of the funds held in the trust account.
- Warrant holders may not receive any funds if the company liquidates.
- Employees of the company may be impacted by the uncertainty surrounding the company's future.
Next Steps
- The company will seek shareholder approval for the business combination with Phytanix Bio.
- The company will work to complete the business combination with Phytanix Bio by November 15, 2025.
- The company will seek to list its securities on Nasdaq Capital Markets upon consummation of the Phytanix Business Combination.
Key Dates
| Date | Description |
|---|---|
| 2021-01-21 | Chain Bridge I incorporated as a Cayman Islands exempted company. |
| 2021-11-09 | Registration statement for the company's Initial Public Offering declared effective. |
| 2021-11-15 | Company consummated its Initial Public Offering. |
| 2022-11-16 | CBG agreed to loan the Company up to $1,200 thousand pursuant to an unsecured non-interest bearing convertible promissory note. |
| 2023-05-10 | Company, CBG, and CB Co-Investment entered into non-redemption agreements. |
| 2023-05-12 | Special Meeting of shareholders held to approve amendment to the company's articles of incorporation. |
| 2023-06-13 | Company received a written notice from Nasdaq indicating that the company was no longer in compliance with the Nasdaq Global Market continued listing criteria. |
| 2023-06-14 | Board approved an agreement to grant of 30,000 RSUs to Roger Lazarus. |
| 2023-09-08 | Company's warrants ceased trading on the Nasdaq Global Market. |
| 2023-12-04 | Company's Class A ordinary shares and Units ceased trading on the Nasdaq Global Market and commenced trading on the Nasdaq Capital Market. |
| 2023-12-29 | Company, CBG, CB Co-Investment and Fulton AC consummated the transactions contemplated by the Securities Purchase Agreement. |
| 2024-01-15 | Board approved extending the company's business operations for an additional month, until February 15, 2024. |
| 2024-02-07 | Company held an extraordinary general meeting of shareholders to approve the Amendment Proposal. |
| 2024-04-01 | Mr. Lazarus, the Chief Financial Officer of the Company notified the Board of his resignation, effective immediately. Andrew Kucharchuk appointed as Chief Financial Officer. |
| 2024-05-09 | Company entered into an Exchange Agreement with Fulton AC. |
| 2024-06-20 | Company received a written notice from Nasdaq indicating that the Company no longer complies with the Nasdaq Capital Market continued listing criteria. |
| 2024-06-26 | Phytanix Bio agreed to loan the Company $1,590,995.12, pursuant to an unsecured non interest bearing promissory note. |
| 2024-07-22 | Company, CB Holdings, Inc., CB Merger Sub 1, Phytanix Bio, and CB Merger Sub 2, Inc., entered into a Business Combination Agreement. |
| 2024-09-13 | Company was notified by Nasdaq that the Company had regained compliance with Public Shareholder Rule. |
| 2024-09-30 | End of the reporting period for the quarterly report. |
| 2024-10-10 | Company filed a Proxy Statement seeking to obtain shareholder approval to extend the termination date. |
| 2024-10-29 | Company and Fulton AC entered into the Dissolution Expense Reimbursement Agreement. |
| 2024-11-07 | Company determined to postpone the extraordinary general meeting of shareholders. |
| 2024-11-11 | Company entered into non-redemption agreements with one or more investors. |
| 2024-11-12 | Company received a letter from Nasdaq stating that the company's securities will be delisted from Nasdaq. |
| 2024-11-14 | Company held its General Meeting at which the shareholders voted to approve the Amendment Proposal. |
| 2024-11-19 | Nasdaq suspended that trading of the Company's Class A ordinary shares and units. |
| 2025-11-15 | Extended Termination Date for the company to complete a business combination. |
Keywords
Business Combination, SPAC, Phytanix Bio, Liquidation, Warrants, Redemption, Trust Account, Financial Results, Going Concern, Derivative Liabilities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.